Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2018 07:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Management to host conference call and webcast this morning at 8:30 a.m. EDTJenrin’s extensive pipeline positions Corbus to be a leader in the treatment of inflammatory and fibrotic diseases with...